Magellan robotic system: first use in peripheral vascular disease


Hansen Medical announced the world’s first uses of the Magellan robotic system in the treatment of peripheral vascular disease. The clinical procedures were performed by Nick Cheshire and the medical team at St Mary’s Hospital, part of the Imperial College Healthcare in London, pioneers in the use of flexible robotics in vascular interventions.

The Magellan robotic system is a new robotic approach in the treatment of vascular disease. The system allows precise catheter navigation of peripheral vessels with a proprietary technology that enables independent distal tip control of a catheter and a sheath, as well as robotic manipulation of a standard guidewire from a centralised, remote workstation. The Magellan was designed to allow precise and predictable catheter navigation of peripheral vessels while reducing procedure time, lessening radiation exposure, lowering procedural fatigue and enabling new procedures.


“Hansen Medical’s new Magellan robotic system opens up the possibility for physicians to offer less invasive endovascular options to a broader group of patients suffering from complex disease,” said Nick Cheshire, head of Circulation Sciences at Imperial College Healthcare. “Imperial College has been pioneering the use of flexible robotics in vascular interventions, and the Magellan robotic system now gives us access to the latest robotic catheter technology that is specifically designed for peripheral vascular interventions.”


“Today’s announcement is a significant milestone in the history of Hansen Medical. It reinforces our commitment to improve the lives of patients, and the physicians that treat and care for them, around the world, and opens up an entirely new market for the use of flexible robotics in the vasculature,” said Hansen Medical’s Bruce Barclay, president and CEO. “St Mary’s is pioneering the use of flexible robotics in vascular interventions, and this is a tremendous opportunity to raise the profile of the Magellan system by generating physician experience and further developing clinical evidence in advance of a full scale commercial launch.”